Moderna hires a chief brand officer to guide vaccine campaigns through 'time of rapid growth'
In the last couple years, Moderna has transformed from a small Cambridge biotech with big dreams into one of the most talked-about drugmakers in the world. In Q1 alone, the company’s mRNA vaccine for Covid-19 pulled in more than $1 billion. Now, it’s beefing up its marketing game.
Moderna is bringing Ogilvy Health veteran Kate Cronin on board as chief brand officer to scale up during “a time of rapid growth,” CEO Stéphane Bancel said Monday.
“Kate has an impressive track record of strategic planning and execution while using creativity and a digital-first mindset to create integrated, best-in-class campaigns for global commercial biopharmaceutical companies,” Bancel said in a statement. “I look forward to partnering with her to amplify Moderna’s story and the promise of mRNA science for patients.”
Cronin studied biology at Smith College in the small but eclectic western Massachusetts city of Northampton. She later went on to conduct research in neurobiology at Cornell University Medical College. Most recently, she was global CEO of the advertising company Ogilvy Health, where she ran public relations and influence, brand strategy, advertising, medical education, market access and patient and consumer engagement.
While at Ogilvy, Cronin led brand and public relations for some big-name pharmas, including Bristol Myers Squibb, Boehringer Ingelheim, Merck and Pfizer.
“What Moderna has achieved is truly inspirational and I’m incredibly excited to be joining a company that has such a tremendous impact on the world,” Cronin said in a statement.
The new appointment comes just weeks after the US government inked a deal for another 200 million doses of Moderna’s Covid-19 vaccine, bringing the country’s total dose order to 500 million. So far, Moderna has delivered around 217 million released doses to the US.
On June 10, Moderna filed for an emergency use authorization in adolescents, based on positive data from 12- to 17-year-olds in the Phase II/III TeenCOVE study. No cases of Covid-19 were seen in participants who received two doses of the vaccine, suggesting a 100% efficacy rate, according to Moderna.
Moderna’s $MRNA stock, which sold for under $20 for most of 2019, is selling for more than $220 apiece.
“I look forward to building the brand and communicating about the future potential for mRNA vaccines and therapeutics and how that science can impact patients’ lives,” Cronin said.